[{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha1\/beta1\/gamma2","graph1":"Sleep","graph2":"Approved","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Aytu BioScience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioScience \/ Not Applicable"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Neos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioScience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Aytu BioScience \/ Aytu BioScience","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioScience \/ Aytu BioScience"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aytu BioScience \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Aytu BioScience \/ Aytu BioPharma"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Rumpus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aytu BioScience \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Aytu BioScience \/ Aytu BioPharma"}]

Find Clinical Drug Pipeline Developments & Deals by Aytu BioScience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.

                          Brand Name : DB102

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2021

                          Lead Product(s) : Enzastaurin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : Denovo Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).

                          Brand Name : AR101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 12, 2021

                          Lead Product(s) : Enzastaurin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : Rumpus Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.

                          Brand Name : Cotempla XR-ODT

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 10, 2020

                          Lead Product(s) : Methylphenidate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Recipient : Neos Therapeutics

                          Deal Size : $44.9 million

                          Deal Type : Merger

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and will be able to be commercialized and supplied within Australia.

                          Brand Name : Zolpimist

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 30, 2020

                          Lead Product(s) : Zolpidem Tartrate

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank